Profile data is unavailable for this security.
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
- Revenue in USD (TTM)323.80m
- Net income in USD170.85m
- Incorporated2006
- Employees126.00
- LocationProtagonist Therapeutics Inc7707 Gateway Blvd Ste 140NEWARK 94560-1160United StatesUSA
- Phone+1 (510) 474-0170
- Fax+1 (302) 636-5454
- Websitehttps://www.protagonist-inc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azenta Inc | 658.62m | -156.38m | 2.25bn | 3.30k | -- | 1.16 | -- | 3.42 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 2.31bn | 436.00 | -- | 2.92 | -- | 6.62 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 2.31bn | 266.00 | -- | -- | -- | 20.94 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.47 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Geron Corp | 29.48m | -201.19m | 2.39bn | 141.00 | -- | 8.19 | -- | 81.18 | -0.3221 | -0.3221 | 0.0469 | 0.4846 | 0.0687 | -- | 1.31 | 209,078.00 | -46.90 | -51.32 | -63.81 | -64.90 | 97.29 | -- | -682.47 | -19,949.13 | 2.74 | -- | 0.2229 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Scholar Rock Holding Corp | 0.00 | -203.85m | 2.41bn | 150.00 | -- | 15.96 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| SpringWorks Therapeutics Inc | 135.49m | -275.16m | 2.46bn | 305.00 | -- | -- | -- | 18.15 | -3.89 | -3.89 | 1.89 | -- | -- | -- | -- | 444,219.70 | -- | -36.97 | -- | -39.49 | 94.52 | -- | -203.09 | -2,176.46 | -- | -- | -- | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Soleno Therapeutics Inc | 0.00 | -131.16m | 2.47bn | 33.00 | -- | 8.89 | -- | -- | -3.31 | -3.31 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -72.82 | -53.90 | -82.94 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| CG Oncology Inc | 650.00k | -75.84m | 2.48bn | 61.00 | -- | 4.46 | -- | 3,816.17 | -1.17 | -1.17 | 0.01 | 8.29 | -- | -- | -- | 10,655.74 | -- | -- | -- | -- | -- | -- | -9,870.92 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -33.03m | 2.48bn | 20.00 | -- | 22.33 | -- | -- | -1.11 | -1.11 | 0.00 | 3.63 | 0.00 | -- | -- | 0.00 | -38.10 | -- | -38.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Protagonist Therapeutics Inc | 323.80m | 170.85m | 2.54bn | 126.00 | 16.13 | 4.83 | 14.80 | 7.85 | 2.68 | 2.68 | 5.24 | 8.94 | 0.6935 | -- | 236.87 | 2,891,027.00 | 36.59 | -35.90 | 39.67 | -41.36 | -- | -- | 52.76 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Keros Therapeutics Inc | 651.00k | -181.57m | 2.63bn | 160.00 | -- | 4.78 | -- | 4,037.05 | -5.21 | -5.21 | 0.0187 | 13.57 | 0.0014 | -- | -- | 4,786.77 | -40.10 | -35.95 | -42.23 | -38.07 | -- | -- | -27,890.94 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.67bn | 525.00 | -- | 8.08 | -- | 136.10 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Ideaya Biosciences Inc | 3.92m | -178.12m | 2.68bn | 124.00 | -- | 2.27 | -- | 682.73 | -2.32 | -2.32 | 0.0515 | 13.67 | 0.0044 | -- | 1.17 | 31,629.03 | -20.09 | -19.17 | -20.87 | -21.05 | -- | -- | -4,541.56 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Janux Therapeutics Inc | 13.05m | -60.54m | 2.77bn | 64.00 | -- | 4.22 | -- | 212.52 | -1.18 | -1.18 | 0.2548 | 12.54 | 0.0241 | -- | -- | 203,890.60 | -11.19 | -- | -11.53 | -- | -- | -- | -463.91 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Protagonist Therapeutics Inc's reporting currency: US Dollar USD
56.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 30 Jun 2024 | 5.84m | 9.92% |
| RTW Investments LPas of 30 Jun 2024 | 5.29m | 8.98% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.23m | 7.18% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.22m | 7.16% |
| BVF Partners LPas of 30 Jun 2024 | 3.32m | 5.64% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.18m | 5.41% |
| Jefferies Investment Advisers LLCas of 30 Jun 2024 | 2.04m | 3.46% |
| Adage Capital Management LPas of 30 Jun 2024 | 2.00m | 3.40% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 1.60m | 2.72% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.37m | 2.33% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
